Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 258

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 258
---
 shares underlying such warrants, have not been registered under the Securities Act,
or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an
effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable
state securities laws.

This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.

About NLS Pharmaceutics

NLS Pharmaceutics is a global biopharmaceutical
company focused on developing next-generation therapies for sleep disorders, neurodegenerative diseases, and metabolic
dysfunctions. Through a strategic licensing agreement with Aexon Labs, NLS is advancing a portfolio of non-sulfonamide dual
orexin receptor agonists (DOXA), including AEX-2 and AEX-41, designed to restore sleep-wake balance, reduce neuroinflammation,
and address metabolic dysregulation.

<div align='center'>2</div>

About Kadimastem

Kadimastem is a clinical stage cell therapy company,
developing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation
of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy
in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes.
IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially
cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem
and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention
and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange
(TASE: KDST).

Forward-Looking Statements

This press release contains expressed or implied
forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and